TNFRSF10D expression as a potential biomarker for cisplatin-induced damage and ovarian tumor relapse prediction
Pathology - Research and Practice · 2024
DOI: 10.1016/j.prp.2024.155592 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pathology - Research and Practice, 2024. Verfasst von Nikole Gontijo Gonçales und 4 weiteren Autor:innen. Beteiligte Einrichtung: Cellular Biology, Research and Development Department, Ezequiel Dias Foundation, Belo Horizonte, Minas Gerais 30510-010, Brazil; Department of Genera…. Hauptthemen laut MEDLINE: Tumor Necrosis Factor Decoy Receptors, Biomarkers, Tumor, Cisplatin, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: Fundação de Amparo à Pesquisa do Estado de Minas Gerais.
Abstract (Originalsprache)
Among gynecological malignancies, ovarian cancer (OC) presents the most challenging diagnostic scenario. Despite exhaustive efforts, up to 90 % of patients treated with taxane/platinum-based chemotherapy experience relapse, leading to poor survival rates. Identifying new molecular markers that can characterize disease aggressiveness, chemoresistance, recurrence risk, and metastasis is crucial. This study aimed to assess the susceptibility of three ovarian tumor cell lines (TOV-21G, SKOV-3, and OV-90) to cisplatin and paclitaxel, and to investigate the influence of these treatments on the mRNA expression of TANK, RIPK1, NFKB1, TNFRSF10D, and TRAF2. Among the cell lines, SKOV-3 ovarian adenocarcinoma cells demonstrated the highest resistance to cisplatin treatment (0.125 mg/mL), followed by TOV-21G (0.076 mg/mL) and OV-90 cells (0.028 mg/mL). Regarding paclitaxel treatment, the SKOV-3 cell line exhibited the highest resistance (1.4 µg/mL), followed by OV-90 (1.3 µg/mL) and TOV-21G cells (0.9 µg/mL). Gene expression analysis after paclitaxel treatment remained unchanged; however, after cisplatin treatment, TNFRSF10D was observed to be upregulated nearly 100-fold in SKOV-3 compared to all other cell lines studied. SKOV-3 is described as cisplatin and tumor necrosis factor-resistant. Despite the defective signaling of the TNFRSF10D receptor for apoptosis, it can activate the NFKB transcription factor through non-canonical TRAIL signaling, contributing to a pro-inflammatory immune response. In light of this, damage associated with cisplatin increases TNFRSF10D expression and may promote cell survival through non-canonical NFKB pathway activation. This suggests that resistance to TRAIL-induced apoptosis in these cells could serve as a promising chemoresistance biomarker in OC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cellular Biology, Research and Development Department, Ezequiel Dias Foundation, Belo Horizonte, Minas Gerais 30510-010, Brazil; Department of General Biology, Federal University of Minas Gerais, Belo Horizonte, Minas G…
- Cellular Biology, Research and Development Department, Ezequiel Dias Foundation, Belo Horizonte, Minas Gerais 30510-010, Brazil; Translational Research Laboratory in Oncology, Mário Penna Institute, Belo Horizonte, MG,…
- Cellular Biology, Research and Development Department, Ezequiel Dias Foundation, Belo Horizonte, Minas Gerais 30510-010, Brazil.
- Department of Gynecology and Obstetrics, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
Förderung
- Fundação de Amparo à Pesquisa do Estado de Minas Gerais
Zitieren
APA
Gonçales, N. G., Gonçalves, B. Ô. P., Silva, L. M., da Silva Filho, A. L., & da Conceição Braga, L. (2024). TNFRSF10D expression as a potential biomarker for cisplatin-induced damage and ovarian tumor relapse prediction. Pathology - Research and Practice. https://doi.org/10.1016/j.prp.2024.155592
Vancouver
Gonçales NG, Gonçalves BÔP, Silva LM, da Silva Filho AL, da Conceição Braga L. TNFRSF10D expression as a potential biomarker for cisplatin-induced damage and ovarian tumor relapse prediction. Pathology - Research and Practice. 2024. doi:10.1016/j.prp.2024.155592
BibTeX
@article{Gonales2024,
author = {Gonçales, Nikole Gontijo and Gonçalves, Bryan Ôrtero Perez and Silva, Luciana Maria and da Silva Filho, Agnaldo Lopes and da Conceição Braga, Letícia},
title = {TNFRSF10D expression as a potential biomarker for cisplatin-induced damage and ovarian tumor relapse prediction},
journal = {Pathology - Research and Practice},
year = {2024},
doi = {10.1016/j.prp.2024.155592}
}
EUVIMED